Madeline Feldman v. Mind Medicine, Inc.

CourtDistrict Court, S.D. New York
DecidedJuly 19, 2024
Docket1:23-cv-06169
StatusUnknown

This text of Madeline Feldman v. Mind Medicine, Inc. (Madeline Feldman v. Mind Medicine, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Madeline Feldman v. Mind Medicine, Inc., (S.D.N.Y. 2024).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK -------------------------------------------------------------X MADELINE FELDMAN, : Plaintiff, : : 23 Civ. 6169 (LGS) -against- : : OPINION & ORDER MIND MEDICINE, INC., : Defendant. : -------------------------------------------------------------X

LORNA G. SCHOFIELD, District Judge: Plaintiff Madeline Feldman brings this employment discrimination action against Defendant Mind Medicine. Defendant moves to dismiss eleven of the fifteen causes of action in the Amended Complaint for failure to state a claim pursuant to Federal Rule of Civil Procedure 12(b)(6).1 The eleven challenged causes of action are brought under the Equal Pay Act of 1963 (“EPA”), the New York Equal Pay Act (“NYEPA”), the New York State Human Rights Law (“NYSHRL”), the New York City Human Rights Law (“NYCHRL”), the Sarbanes-Oxley Act of 2002 (“SOX”) and New York common law. For the reasons below, Defendant’s motion is granted in part and denied in part. I. BACKGROUND The following facts are taken from the Amended Complaint. The Amended Complaint’s allegations are assumed to be true for purposes of this motion and are construed in the light most favorable to Plaintiff as the non-moving party. See Hu v. City of New York, 927 F.3d 81, 88 (2d Cir. 2019). A. Wage Discrimination Allegations Plaintiff is a former employee of Defendant. She first began working for Defendant in

1 Defendant does not move to dismiss the claims brought under Title VII of the Civil Rights Act of 1964 and the Americans with Disabilities Act. June 2019 as a consultant before becoming one of Defendant’s first full-time employees in April 2020, as Director of Administration & Operations. She later became Director of Strategy and Operations and then Chief of Staff to Chief Business Officer/Chief Technology Officer (“CBO/CTO”) Bradford Cross. From 2019 to 2022, she helped take the company public, scale the team to about 75 full-time employees and lead the team through several changes in leadership. During this time, she worked side-by-side with the founders and co-chief executive

officers (“CEOs”) Jamon A. Rahn and Stephen Hurst to launch the company. The Amended Complaint alleges that Defendant paid Plaintiff less than her male colleagues with substantially equal jobs and that Defendant systematically gave men more prestigious titles and promotion opportunities than it gave women. For example, in August 2020, Defendant hired an entry-level male analyst and awarded him more stock options than Defendant awarded Plaintiff. In addition, when Defendant hired a female director in the operations department (“Female Director 1”) in October 2020, CEO Rahn authorized Plaintiff to offer a salary of only $80,000, even though Female Director 1 had more experience than a male coworker who earned $120,000. Plaintiff questioned whether $80,000 was an appropriate salary

for Female Director 1, since Female Director 1 would be working in New York City. CEO Rahn responded that Defendant did not offer pay differentials for geographic costs of living. Plaintiff discussed the pay disparity with Chief Operating Officer (“COO”) Carol Nast, who confirmed her knowledge of CEO Rahn’s “sexist behavior.” In December 2020, CEO Rahn promoted Plaintiff to Level 6 (Senior Director) and two male coworkers (“Male Coworkers 1 and 2”) to Level 7 (Vice President), even though Male Coworkers 1 and 2 each had fewer responsibilities than Plaintiff. At one point, Defendant suggested that Male Coworker 2 report to Plaintiff, even though his title was higher than hers. By June or July 2021, Defendant re-leveled many of its positions to make its titles, seniority levels and pay rates uniform across the company with the integration of a recently acquired company. Although Plaintiff was re-leveled to Level 5 (Director) and Male Coworkers 1 and 2 were each re-leveled to the lower tier of Level 4, the Male Coworkers kept their previous Level 7 vice president titles, and Defendant consistently paid Plaintiff significantly less than it paid either Male Coworker 1 or Male Coworker 2. For instance, Plaintiff’s starting salary was $100,000, while Male Coworker 1 and Male Coworker 2 earned $120,000 and $150,000, respectively. In

addition, Defendant granted Plaintiff 120,000 employee stock options, while it granted Male Coworker 1 and Male Coworker 2 300,000 and 450,000 stock options, respectively. In August 2021, Defendant hired a male coworker (“Male Coworker 3”) to take over many of Plaintiff’s IT responsibilities. Defendant paid Male Coworker 3 significantly more than Plaintiff and gave him a higher equity grant, even though Male Coworker 3 did not have other responsibilities Plaintiff had, such as managing a staff. Throughout Plaintiff’s time with the company, Defendant repeatedly promised Plaintiff a raise and increase in equity but never fulfilled its promise. In December 2021 or January 2022, while Plaintiff was on a medical leave of absence, Defendant terminated the employment of CBO/CTO Cross. When Plaintiff returned to work in

February 2022, Defendant had completely changed her job. Defendant assigned Plaintiff to a role that was the opposite of her skillset, having reassigned her staff to other projects and reassigned her previous responsibilities to other co-workers. In February or March 2022, Defendant informed Plaintiff that it was reducing her target bonus for 2021 from 40% of her salary to 30%. While Plaintiff negotiated to keep the 40% bonus for 2021, her new supervisor, Vice President of Global Operations Jakub Klimes, changed her target to 30% for 2022. Defendant did not reduce bonus targets for any male employees or employees who did not oppose Defendant’s discriminatory compensation practices. Klimes did not follow Defendant’s usual process for Plaintiff’s performance evaluation, most troublingly by failing to include the traditional “Growth Plan” for Plaintiff. B. SOX Allegations The Amended Complaint alleges that Plaintiff reported various violations of securities laws and regulations to her supervisors from the spring of 2021 to December 2021. After Defendant failed to disclose to shareholders its March 2021 termination of COO Nast’s employment, Plaintiff discussed this omission with CBO/CTO Cross because the company

public disclosure policy specifically listed COO as a material position. The company eventually disclosed the separation in May 2021. From May to December 2021, Plaintiff raised concerns to her supervisor CBO/CTO Cross about Defendant’s lack of certain internal controls, including that key employees were not subject to nondisclosure agreements that would prevent them from disclosing or using Defendant’s material information. Plaintiff raised the issue with Defendant’s executives, counsel and board members, but Defendant repeatedly told Plaintiff that the executive agreements were in progress and would be finished soon. In June or July 2021, Plaintiff reported her concerns that multiple employees and board

members engaged in insider trading by using their knowledge of material and undisclosed information and the pumping of press releases in the days leading up to their sales. Plaintiff reported her concerns to CBO/CTO Cross, who escalated Plaintiff’s concerns and requested a third-party investigation, which never occurred. In June 2021, Plaintiff became involved with the company’s NASDAQ Readiness Project, whose purpose was to resolve various SOX concerns and replace the heads of the legal and finance departments, who were implicated in insider trading and other securities concerns.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

National Railroad Passenger Corporation v. Morgan
536 U.S. 101 (Supreme Court, 2002)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Mullins v. City of New York
626 F.3d 47 (Second Circuit, 2010)
Hill v. Curcione
657 F.3d 116 (Second Circuit, 2011)
Levion v. Societe Generale
503 F. App'x 62 (Second Circuit, 2012)
Levion v. Societe Generale
822 F. Supp. 2d 390 (S.D. New York, 2011)
Hu v. City of New York
927 F.3d 81 (Second Circuit, 2019)
Rich v. Fox News Network, LLC
939 F.3d 112 (Second Circuit, 2019)
Daly v. Citigroup Inc.
939 F.3d 415 (Second Circuit, 2019)
Dane v. UnitedHealthcare Ins. Co.
974 F.3d 183 (Second Circuit, 2020)
Dixon v. Von Blanckensee
994 F.3d 95 (Second Circuit, 2021)
Kaplan v. Lebanese Canadian Bank
999 F.3d 842 (Second Circuit, 2021)
Bensch v. Estate of Umar
2 F.4th 70 (Second Circuit, 2021)
Georgia Malone & Co. v. Rieder
973 N.E.2d 743 (New York Court of Appeals, 2012)
Farash v. Sykes Datatronics, Inc.
452 N.E.2d 1245 (New York Court of Appeals, 1983)
Mance v. Mance
128 A.D.2d 448 (Appellate Division of the Supreme Court of New York, 1987)
Farina v. Bastianich
116 A.D.3d 546 (Appellate Division of the Supreme Court of New York, 2014)
Villnave Constr. Servs., Inc. v. Crossgates Mall Gen. Co. Newco, LLC
201 A.D.3d 1183 (Appellate Division of the Supreme Court of New York, 2022)
Mucerino v. Firetector, Inc.
306 A.D.2d 330 (Appellate Division of the Supreme Court of New York, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
Madeline Feldman v. Mind Medicine, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/madeline-feldman-v-mind-medicine-inc-nysd-2024.